Banque Pictet & Cie SA Has $2.71 Million Stock Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Banque Pictet & Cie SA increased its stake in Vaxcyte, Inc. by 43.8% during Q2, owning approximately 83,372 shares worth $2.71 million.
• Vaxcyte's shares recently opened at $33.98, with a one year range between $27.66 and $118.62.
• Recent analyst ratings show a consensus of Buy for Vaxcyte, with a price target averaging $106.25.

Banque Pictet & Cie SA lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 43.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 83,372 shares of the company's stock after purchasing an additional 25,395 shares during the period. Banque Pictet & Cie SA owned approximately 0.06% of Vaxcyte worth $2,710,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PCVX. RA Capital Management L.P. raised its position in shares of Vaxcyte by 40.3% during the first quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company's stock worth $460,262,000 after purchasing an additional 3,499,959 shares during the period. Wellington Management Group LLP raised its position in shares of Vaxcyte by 44.4% during the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company's stock worth $242,303,000 after purchasing an additional 1,972,918 shares during the period. Baker BROS. Advisors LP raised its position in shares of Vaxcyte by 1,211.0% during the first quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company's stock worth $24,200,000 after purchasing an additional 592,000 shares during the period. Nuveen LLC acquired a new stake in shares of Vaxcyte during the first quarter worth $20,988,000. Finally, Fiera Capital Corp acquired a new stake in shares of Vaxcyte during the first quarter worth $13,563,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $33.98 on Friday. The business's 50-day moving average price is $32.52 and its two-hundred day moving average price is $36.50. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $118.62. The company has a market capitalization of $4.41 billion, a P/E ratio of -8.27 and a beta of 1.04.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the firm posted ($1.10) earnings per share. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Upgrades and Downgrades

PCVX has been the topic of several recent analyst reports. The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, September 12th. They set a "neutral" rating and a $38.00 price target on the stock. Cowen reissued a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $106.25.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.